Clinical Trial 7037

Jonesboro, AR 72401


Study Summary:

A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)


Qualified Participants Must:

• Have been recently hospitalized for ACS between 4 - 8 weeks after Index Event, and whose residual cardiovascular risk may benefit from an increase in HDL-C
• New ECG Findings


Qualified Participants May Receive:

A stipend for their time and efforts and investigational product.


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.